JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Steinmetz, M.
Right arrow Articles by Schlatter, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steinmetz, M.
Right arrow Articles by Schlatter, E.

Vol. 294, Issue 3, 963-968, September 2000

Influence of Purinoceptor Antagonism on Diadenosine Pentaphosphate-Induced Hypotension in Anesthetized Rats1

Martin Steinmetz, Truc Van Le, Peter Hollah, Gert Gabriëls, Helge Hohage, Karl Heinz Rahn and Eberhard Schlatter

Medizinische Poliklinik, Experimentelle Nephrologie, Westfälische Wilhelms-Universität, Münster, Germany

Diadenosine polyphosphates (ApnA; n = 3-6) are potent vasoactive agents in isolated vessels. Information on effects of ApnA in vivo is still limited despite the fact that these compounds are starting to be used in humans. This study was designed to compare the effects of ApnA and their possible metabolites on blood pressure in vivo and to functionally identify purinoceptors involved in their action. All four ApnA and their degradation products induced a sustained drop of mean arterial blood pressure during i.v. infusion, which was fully reversible. The rank order of potency was Ap4A >=  Ap6A > Ap5A = Ap3A = ATP = ADP > AMP >=  adenosine, suggesting that the hypotensive effect is predominantly evoked by the original dinucleotides and not by their degradation products. The hypotensive effect of Ap5A was reduced by the P2X and P2Y1 purinoceptor antagonist pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid, the A1 purinoceptor antagonist 8-cyclopentyl-1,3-dipropylxanthine, and the A2 purinoceptor antagonist 3,7-dimethyl-1-propargylxanthine. The hypertensive effect by the prototype P2X receptor agonist alpha beta -methylene ATP was inhibited by pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid, too. Purinoceptor antagonists reduced the maximal effects of the agonists indicating a noncompetitive inhibition. In summary, the reported vasocontractile effect of ApnA seems to be limited to isolated preparations under resting tone conditions; however, the systemic cardiovascular effects of all four ApnA are hypotensive, also making them candidates for blood pressure reduction in humans. These effects are fast in onset and easily reversible. Activation of different purinoceptors in the vasculature (most probably P2Y1 and A2 receptors) contributes to the Ap5A-induced decrease of mean arterial blood pressure.


1 This study was supported by a grant from the Center for Interdisciplinary Clinical Research (IZKF, project A1) at the Medical Faculty of the University of Münster (BMBF 01 KS 9604/0). A part of this work was presented at the Congress of Nephrology, Erlangen, Germany, 1998, and is published in abstract form (Schlatter et al., 1998).


0022-3565/00/2943-0963$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Cardiovasc ResHome page
G. Gabriels, K. H. Rahn, E. Schlatter, and M. Steinmetz
Mesenteric and renal vascular effects of diadenosine polyphosphates (APnA)
Cardiovasc Res, October 1, 2002; 56(1): 22 - 32.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Steinmetz, A.-K. Janssen, F. Pelster, K. H. Rahn, and E. Schlatter
Vasoactivity of Diadenosine Polyphosphates in Human Small Mesenteric Resistance Arteries
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 787 - 794.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.